Report Highlights

Contact and Intraocular Lenses in the U.S.: Market Overview

The U.S. contact and intraocular lens market was valued at USD 7.8 billion in 2024, with contact lenses contributing roughly USD 5.6 billion and intraocular lenses USD 2.2 billion. Demand is structured around eye care professionals who prescribe and fit lenses, while Johnson & Johnson Vision, Alcon, Bausch + Lomb and CooperVision control most manufacturing and distribution. Private sector innovation sets product design, particularly silicone hydrogel materials and premium intraocular optics. Retail optical chains and online sellers have expanded volume since 2003, though clinics still capture the majority of revenue.

Government has shaped the market mainly through regulation and payment rules rather than direct purchasing. The Food and Drug Administration classifies soft contact lenses as Class II devices under 21 CFR 886.5916 and intraocular lenses as Class III devices requiring premarket approval, which restricts entry and protects incumbent share. The Centers for Medicare & Medicaid Services sets Part B payment for cataract surgery, so federal reimbursement decisions dominate the intraocular segment, while contact lenses remain largely a private, cash-pay category.

Policy-Driven Growth in U.S. Contact and Intraocular Lenses

The Fairness to Contact Lens Consumers Act (Public Law 108-164, 2003) and the FTC Contact Lens Rule under 16 CFR Part 315 require prescribers to release prescriptions and verify orders from sellers. This mechanism lets online retailers and mass merchants compete on price, shifting volume away from eye care practices and expanding total unit demand. Medicare Part B cataract coverage, billed under CPT 66984, pays for one standard intraocular lens per eye, and more than 3.5 million U.S. cataract procedures annually sustain a predictable replacement-lens base.

The Medical Device User Fee Amendments of 2022 (MDUFA V, covering fiscal years 2023 to 2027) fund FDA premarket review staff through industry fees, shortening review cycles for new intraocular optics. Faster approvals allow manufacturers such as Alcon and Johnson & Johnson Vision to launch extended depth-of-focus and toric lenses sooner, translating directly into premium volume growth. Each approval pulls forward cash-pay procedures among patients aged 65 and older, who account for most cataract surgery volume.

Regulatory Barriers and Compliance Costs for U.S. Lenses

Intraocular lenses require FDA premarket approval under 21 CFR Part 814, a process that typically runs for multiple years and consumes substantial clinical trial budgets administered through Investigational Device Exemptions under 21 CFR Part 812. Contact lenses face Class II 510(k) clearance, but each new material or wear modality requires supporting clinical data. State optometry boards license fitting practices, and the Contact Lens Rule requires written prescription verification, adding administrative cost to each online order.

The Quality Management System Regulation, effective 2 February 2026, replaces the Quality System Regulation at 21 CFR Part 820 with requirements aligned to ISO 13485, compelling plants in Europe and Asia to re-document design controls. Unique Device Identification rules under 21 CFR Part 830 add labelling and database costs per SKU. Section 301 tariffs on Chinese-origin components raise landed costs for lower-priced lens suppliers, while FDA inspectors enforce compliance at foreign and domestic sites alike.

Policy-Created Opportunities in U.S. Contact and Intraocular Lenses

Myopia management presents the clearest policy-created opportunity. CooperVision's MiSight 1 day received FDA clearance in 2019 as the first contact lens indicated to slow myopia progression in children, and paediatric prescriptions are migrating into specialist practices. Each child fitted adds years of repeat replacement volume, making paediatric myopia control a multi-decade revenue stream for manufacturers that secure fitting protocols and clinician training programmes.

Ambulatory surgical centres represent a second opportunity. CMS includes cataract surgery on the Medicare ASC Covered Procedures List, enabling facility payment in lower-cost settings and driving demand for premium lens inventory outside hospitals. Manufacturers that supply ASC chains with bundled contracts capture share as sites grow. Veterans Health Administration national contracting through the Federal Supply Schedule adds a third channel for standardised intraocular lens purchasing.

Market at a Glance

Leading Market Participants

• Alcon
• Johnson & Johnson Vision
• Bausch + Lomb
• CooperVision
• STAAR Surgical
• Hoya Surgical Optics
• Carl Zeiss Meditec
• Rayner
• Menicon
• Cooper Companies

Regulatory and Policy Environment for U.S. Lenses

The primary legislation is the Federal Food, Drug, and Cosmetic Act as amended by the Medical Device Amendments of 1976 (Public Law 94-295), administered by the FDA Center for Devices and Radiological Health. Compliance requires PMA or 510(k) approval, Medical Device Reporting under 21 CFR Part 803, and conformance with 21 CFR Part 820 once the QMSR takes effect on 2 February 2026. The Fairness to Contact Lens Consumers Act, enforced by the Federal Trade Commission, adds prescription release obligations for all contact lens sellers.

Upcoming changes include MDUFA VI negotiations ahead of fiscal 2028 reauthorization, since MDUFA V expires on 30 September 2027, shaping FDA review timelines for intraocular optics. Compared with regional peers, the U.S. framework offers faster premarket pathways than the European Union, where Regulation (EU) 2017/745 relies on notified bodies and extended transition deadlines. It is more market-driven than Canada's Medical Devices Regulations (SOR/98-282), while Japan's reimbursement pricing through National Health Insurance remains more centralised.

Long-Term Policy Outlook for U.S. Contact and Intraocular Lenses

By 2032, Medicare payment reform is the largest policy variable. CMS annual Physician Fee Schedule updates could revise cataract payment bundles, and any expansion of Part B coverage to presbyopia-correcting lenses would move premium lens demand from cash-pay to insured volume. Analysts expect Medicare Advantage plans to expand vision riders, which would shift elective premium lens purchases toward insurer-negotiated contracts. Manufacturers should expect pricing pressure in standard monofocal categories as CMS reviews payment adequacy.

Regulatory change will also reshape competition. Full QMSR enforcement from 2026 and MDUFA VI commitments will raise the compliance threshold, favouring large manufacturers with established quality infrastructure over smaller importers. Myopia management reimbursement policy will determine whether paediatric control lenses become a mainstream covered category. The Federal Trade Commission will continue enforcing prescription release, keeping online channels competitive through 2032. Expect consolidation among second-tier suppliers by 2032.